Registry of Lobbyists
Active
-
Last Updated:
2024-03-26
| Subject matters | Details | Categories |
|---|---|---|
|
Health
|
Discuss Canada's response to the proposed bulk importation of medications from Canada to the United States.
|
Policies or Program,
Regulation
|
|
Health
|
Ensure access to a comprehensive range of medicines and vaccines in Canada and protect access to clinical trials, while helping to rebuild domestic capacities to develop and make drugs and vaccines.
|
Policies or Program
|
|
Health
|
Ensure patient organizations are consulted and provide feedback on policies and other initiatives from the Canadian Drug Agency.
|
Policies or Program
|
|
Health
|
Provide input on a national strategy for drugs for rare diseases.
|
Policies or Program
|
|
Health
|
Provide input on proposed agile regulations and guidance for licensing drugs and medical devices.
|
Regulation
|
|
Health
|
Recommend that the government and regulators adopt proactive approaches to communicating drug supply and shortages issues and measures to address them.
|
Policies or Program,
Regulation
|
|
Health
|
Recommend that the government study and provide public interest funding so that the voices of patients, their needs and interests can be more adequately represented in public policy and regulatory matters.
|
Grant, Contribution or Other Financial Benefit,
Policies or Program
|
|
Health
|
Share patient groups perspectives on drug pricing and access to medications/vaccines/clinical trials, specifically regulations and guidelines related to the Patented Medicine Prices Review Board, along with feedback on their policies and practices, and processes related to PMPRB.
|
Policies or Program,
Regulation
|
|
Health
|
Share patient groups perspectives on national pharmacare and national formulary proposals.
|
Legislative Proposal, Bill or Resolution,
Policies or Program
|
| Subject matters | Details | Categories |
|---|---|---|
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Discuss Canada's response to the proposed bulk importation of medications from Canada to the United States.
|
Policies or Program,
Regulation
|
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Ensure access to a comprehensive range of medicines and vaccines in Canada and protect access to clinical trials, while helping to rebuild domestic capacities to develop and make drugs and vaccines.
|
Policies or Program
|
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Ensure patient organizations are consulted and provide feedback on policies and other initiatives from the Canadian Drug Agency.
|
Policies or Program
|
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Ensure patient organizations are consulted and provide feedback during the proposed creation of the Canadian Drug Agency as outlined in Budget 2019.
|
Policies or Program
|
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Learn more about and provide feedback on plans around COVID-19 vaccines.
|
Policies or Program
|
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Provide input on a national strategy for drugs for rare diseases.
|
Policies or Program
|
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Provide input on proposed agile regulations and guidance for licensing drugs and medical devices.
|
Regulation
|
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Provide input on the Canadian Drug Agency.
|
Policies or Program
|
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Recommend that the government and regulators adopt proactive approaches to communicating drug supply and shortages issues and measures to address them.
|
Policies or Program,
Regulation
|
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Recommend that the government study and provide public interest funding so that the voices of patients, their needs and interests can be more adequately represented in public policy and regulatory matters.
|
Grant, Contribution or Other Financial Benefit,
Policies or Program
|
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Share patient groups perspectives on drug pricing and access to medications/vaccines/clinical trials, specifically regulations and guidelines related to the Patented Medicine Prices Review Board, along with feedback on their policies and practices, and processes related to PMPRB.
|
Policies or Program,
Regulation
|
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Share patient groups perspectives on national pharmacare and national formulary proposals.
|
Legislative Proposal, Bill or Resolution,
Policies or Program
|
Communication techniques that have been used or are expected to be used in the course of the undertaking: